Contact
searchSearch
HMP Global
Login

Colorectal Cancer

Colorectal Cancer
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Annalice Gandini, IRCCS
Videos
Real-World Neoadjuvant Immunotherapy Demonstrates High Response Rates in dMMR/MSI Colorectal Cancer
07/14/2026
Annalice Gandini
Annalice Gandini, IRCCS, discusses results from the real-world AGEO-NEO-MSI study which demonstrated that neoadjuvant immunotherapy produced high complete response rates in patients with nonmetastatic dMMR/MSI-H colorectal cancer while...
Annalice Gandini, IRCCS, discusses results from the real-world AGEO-NEO-MSI study which demonstrated that neoadjuvant immunotherapy produced high complete response rates in patients with nonmetastatic dMMR/MSI-H colorectal cancer while...
Annalice Gandini, IRCCS,...
07/14/2026
Oncology
Gunnar Folprecht, MD, PhD
Videos
Clinical Utility of ctDNA-Guided Adjuvant Therapy in Stage II Colon Cancer
07/01/2026
Gunnar Folprecht, MD, PhD
Gunnar Folprecht, MD, PhD, discusses results from the CIRCULATE trial showing that tumor-informed circulating tumor DNA testing identified patients with stage II colon cancer who derived significant benefit from adjuvant chemotherapy,...
Gunnar Folprecht, MD, PhD, discusses results from the CIRCULATE trial showing that tumor-informed circulating tumor DNA testing identified patients with stage II colon cancer who derived significant benefit from adjuvant chemotherapy,...
Gunnar Folprecht, MD, PhD,...
07/01/2026
Oncology
Eiji Oki, MD, PhD, FACS
Videos
ctDNA Dynamics Predict Outcomes After Adjuvant Chemotherapy in Patients With Colorectal Cancer
06/09/2026
Eiji Oki, MD, PhD
Eiji Oki, MD, PhD, discusses results from the CIRCULATE-Japan trial showing that serial ctDNA dynamics during adjuvant chemotherapy strongly predict recurrence risk and may help personalize treatment strategies in colorectal cancer.
Eiji Oki, MD, PhD, discusses results from the CIRCULATE-Japan trial showing that serial ctDNA dynamics during adjuvant chemotherapy strongly predict recurrence risk and may help personalize treatment strategies in colorectal cancer.
Eiji Oki, MD, PhD, discusses...
06/09/2026
Oncology
Ramón Salazar, MD, PhD
Videos
Anti-EGFR–First Strategy Demonstrates Superior Initial Disease Control in Patients With Metastatic Colorectal Cancer
06/09/2026
Ramon Salazar, MD, PhD
Ramón Salazar, MD, PhD, discusses results from the phase 3 CR-SEQUENCE trial showing that first-line panitumumab-based therapy significantly improved response rates and progression-free survival compared with a bevacizumab-first strategy in...
Ramón Salazar, MD, PhD, discusses results from the phase 3 CR-SEQUENCE trial showing that first-line panitumumab-based therapy significantly improved response rates and progression-free survival compared with a bevacizumab-first strategy in...
Ramón Salazar, MD, PhD,...
06/09/2026
Oncology
Filippo Pietrantonio, MD
Videos
ctDNA Clearance Predicts Outcomes in KRAS G12C-Mutated Metastatic Colorectal Cancer
06/09/2026
Filippo Pietrantonio, MD
Filippo Pietrantonio, MD, discusses post hoc analysis results from the CodeBreaK 300 trial which showed that early ctDNA clearance strongly correlates with tumor response and improved survival outcomes in patients with KRAS G12C-mutated...
Filippo Pietrantonio, MD, discusses post hoc analysis results from the CodeBreaK 300 trial which showed that early ctDNA clearance strongly correlates with tumor response and improved survival outcomes in patients with KRAS G12C-mutated...
Filippo Pietrantonio, MD,...
06/09/2026
Oncology
Scott Kopetz, MD, PhD
Videos
Encorafenib and Cetuximab Plus FOLFIRI Improves Outcomes in BRAF V600E-Mutant Metastatic Colorectal Cancer
06/04/2026
Scott Kopetz, MD, PhD
Scott Kopetz, MD, PhD, FASCO, discusses phase 3 BREAKWATER Cohort 3 results showing that first-line encorafenib plus cetuximab and FOLFIRI improved response rates, progression-free survival, and overall survival vs standard therapy in BRAF...
Scott Kopetz, MD, PhD, FASCO, discusses phase 3 BREAKWATER Cohort 3 results showing that first-line encorafenib plus cetuximab and FOLFIRI improved response rates, progression-free survival, and overall survival vs standard therapy in BRAF...
Scott Kopetz, MD, PhD, FASCO,...
06/04/2026
Oncology
Paul Oberstein, MD
Videos
Amivantamab Demonstrates Activity Across Multiple RAS/BRAF Wild-Type Metastatic Colorectal Cancer Subgroups
05/27/2026
Paul Oberstein, MD
Paul Oberstein, MD, discusses results from the phase 1 OrigAMI-1 trial evaluating amivantamab monotherapy in patients with previously treated RAS/BRAF wild-type metastatic colorectal cancer, highlighting encouraging activity across multiple...
Paul Oberstein, MD, discusses results from the phase 1 OrigAMI-1 trial evaluating amivantamab monotherapy in patients with previously treated RAS/BRAF wild-type metastatic colorectal cancer, highlighting encouraging activity across multiple...
Paul Oberstein, MD, discusses...
05/27/2026
Oncology
Ismail Gögenur, MD, DMSc
Videos
Neoadjuvant Pembrolizumab in Localized Mismatch Repair–Deficient Colon Cancer
05/15/2026
Ismail Gögenur, MD
Ismail Gögenur, MD, DMSc, discusses results from the RESET-C trial evaluating a single cycle of neoadjuvant pembrolizumab in patients with mismatch repair–deficient colon cancer.
Ismail Gögenur, MD, DMSc, discusses results from the RESET-C trial evaluating a single cycle of neoadjuvant pembrolizumab in patients with mismatch repair–deficient colon cancer.
Ismail Gögenur, MD, DMSc,...
05/15/2026
Oncology
Andrew Renehan, MD, PhD
Videos
Survival and Quality of Life Drive Treatment Preferences in Rectal Cancer
04/16/2026
Andrew Renehan, MD, PhD
Andrew Renehan, MD, discusses results from the PrefCoRe study showing that overall survival and quality of life were the strongest factors influencing patient preferences for watch-and-wait versus surgery after clinical complete response in...
Andrew Renehan, MD, discusses results from the PrefCoRe study showing that overall survival and quality of life were the strongest factors influencing patient preferences for watch-and-wait versus surgery after clinical complete response in...
Andrew Renehan, MD, discusses...
04/16/2026
Oncology
Davide Ciardiello, MD
Videos
HER2 Alterations May Influence Response to Cetuximab in Metastatic Colorectal Cancer
03/11/2026
Davide Ciardiello, MD
Davide Ciardiello, MD, discusses an exploratory analysis of the CAPRI2-GOIM study showing that HER2 mutations and HER2 amplification may have distinct prognostic and predictive implications for patients with RAS/BRAF wild-type metastatic...
Davide Ciardiello, MD, discusses an exploratory analysis of the CAPRI2-GOIM study showing that HER2 mutations and HER2 amplification may have distinct prognostic and predictive implications for patients with RAS/BRAF wild-type metastatic...
Davide Ciardiello, MD, discusses...
03/11/2026
Oncology

Recent News

News
IO102-IO103 Plus Nivolumab and Relatlimab Demonstrates Encouraging Activity in Unresectable Melanoma
08/05/2026
Stephanie Holland
A phase 2 trial demonstrated that the investigational cancer vaccine IO102-IO103 combined with nivolumab and relatlimab achieved a 60% objective response rate in previously untreated unresectable melanoma, supporting further evaluation of the...
A phase 2 trial demonstrated that the investigational cancer vaccine IO102-IO103 combined with nivolumab and relatlimab achieved a 60% objective response rate in previously untreated unresectable melanoma, supporting further evaluation of the...
A phase 2 trial demonstrated...
08/05/2026
Oncology
News
HBI-8000 Plus Nivolumab Significantly Improves Progression-Free Survival in Advanced Melanoma
08/05/2026
Stephanie Holland
Topline results from a global phase 3 trial demonstrated that HBI-8000 plus nivolumab significantly improved progression-free survival compared with nivolumab alone in patients with advanced melanoma, supporting the combination as a potential...
Topline results from a global phase 3 trial demonstrated that HBI-8000 plus nivolumab significantly improved progression-free survival compared with nivolumab alone in patients with advanced melanoma, supporting the combination as a potential...
Topline results from a global...
08/05/2026
Oncology
FDA Approval
FDA Approves Rituximab Biosimilar for the Treatment of B-Cell Malignancies and Autoimmune Diseases
08/04/2026
Stephanie Holland
The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...
The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...
The FDA has approved a rituximab...
08/04/2026
Oncology
FDA Alerts
FDA Advisory Committee Backs RP1 Plus Nivolumab for Advanced Melanoma in 10-3 Vote
07/31/2026
Stephanie Holland
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 that efficacy findings from the phase 2 IGNYTE trial of RP1 (vusolimogene oderparepvec) plus nivolumab are clinically meaningful, supporting the investigational...
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 that efficacy findings from the phase 2 IGNYTE trial of RP1 (vusolimogene oderparepvec) plus nivolumab are clinically meaningful, supporting the investigational...
The FDA's Cellular, Tissue, and...
07/31/2026
Oncology
FDA Alerts
Subcutaneous Amivantamab Receives FDA Priority Review for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
07/30/2026
Emily Estrada
The FDA granted Priority Review to subcutaneous amivantamab and hyaluronidase for previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma, supported by results from the phase 1b/2 OrigAMI-4 trial.
The FDA granted Priority Review to subcutaneous amivantamab and hyaluronidase for previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma, supported by results from the phase 1b/2 OrigAMI-4 trial.
The FDA granted Priority Review...
07/30/2026
Oncology
News
Regorafenib Producess High Response and Durable Disease Control in KIT-Mutant Advanced Melanoma
07/29/2026
Stephanie Holland
The phase 2 RegoMel trial demonstrated that continuous daily regorafenib produced clinically meaningful antitumor activity in heavily pretreated advanced melanoma, with particularly high response rates in KIT-mutant disease and encouraging...
The phase 2 RegoMel trial demonstrated that continuous daily regorafenib produced clinically meaningful antitumor activity in heavily pretreated advanced melanoma, with particularly high response rates in KIT-mutant disease and encouraging...
The phase 2 RegoMel trial...
07/29/2026
Oncology
News
Ceralasertib Plus Durvalumab Demonstrates Limited Activity in PD-L1-Resistant Advanced Melanoma
07/29/2026
Stephanie Holland
The phase 2 MONETTE trial found that ceralasertib, administered alone or in combination with durvalumab, produced low response rates in patients with anti–PD-L1-resistant advanced melanoma, while exploratory analyses identified higher...
The phase 2 MONETTE trial found that ceralasertib, administered alone or in combination with durvalumab, produced low response rates in patients with anti–PD-L1-resistant advanced melanoma, while exploratory analyses identified higher...
The phase 2 MONETTE trial found...
07/29/2026
Oncology
News
Real-World Study Demonstrates Rapid Pain Relief, Durable Disease Control, and Manageable Safety With Nirogacestat in Young Adults With Desmoid Tumors
07/28/2026
Emily Estrada
A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...
A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...
A real-world study found that...
07/28/2026
Oncology
News
Real-World Study Highlights Evolving Treatment Patterns and Petsistent Diagnostic Challenges in Patients With Desmoid Tumors
07/28/2026
Emily Estrada
Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...
Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...
Real-world findings demonstrated...
07/28/2026
Oncology
News
Real-World Analysis Identifies Performance Status as a Key Predictor of Outcomes With Tarlatamab in Extensive-Stage Small Cell Lung Cancer
07/28/2026
Stephanie Holland
Results from the largest real-world analysis of tarlatamab to date demonstrated that baseline performance status was a major determinant of clinical outcomes in patients with previously treated extensive-stage small cell lung cancer, whereas...
Results from the largest real-world analysis of tarlatamab to date demonstrated that baseline performance status was a major determinant of clinical outcomes in patients with previously treated extensive-stage small cell lung cancer, whereas...
Results from the largest...
07/28/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use